血清中期因子水平在非小细胞肺癌中的价值研究

Levels of midkine in serum of patients with non-small cell lung cancer and the clinical significance

目的检测非小细胞肺癌（NSCLC）患者血清中期因子（Midkine,MK）的水平,探讨其与NSCLC关系。方法采用酶联免疫吸附试验（ELISA）分别测定52例NSCLC患者、52例肺炎患者和52例健康对照者的血清MK的水平,探讨其与NSCLC的临床病理特征和治疗效果关系。结果 NSCLC患者血清MK水平明显高于肺炎组和健康对照组,差异具有统计学意义（P〈0.05）;吸烟的患者血清MK水平明显高于不吸烟患者（P〈0.05）。NSCLC患者血清Ⅲ~Ⅳ期MK水平高于Ⅰ~Ⅱ期（P〈0.05）,腺癌MK水平与鳞癌比较差异无统计学意义（P〉0.05）。有淋巴结转移的NSCLC患者MK水平明显高于无淋巴结转移者（P〈0.05）。同时,对其中的48例NSCLC患者进行治疗后血清MK水平检测,与治疗前比较血清MK明显降低,差异具有统计学意义（P〈0.05）。结论 NSCLC患者血清MK水平与其病理类型、临床分期密切相关,也与患者本身是否吸烟有联系,其是判断临床治疗效果的可靠指标。

Objective To detect the levels ofmidkine （MK） in the serum of patients with non-small cell lung cancer （NSCLC）, and to explore the relationship between MK levels and NSCLC. Methods Enzyme-linked immuno- sorbent assay （ELISA） was used to detect the levels of serum MK in 52 patients with NSCLC, 52 patients with pneu- monia and 52 healthy people. The relationships between MK levels and clinical pathological characteristics, treatment effect in non-small cell lung cancer were analyzed. Results MK levels were significantly higher in NSCLC patients than patients with pneumonia and healthy people （P〈0.05）, in smoking patients than non-smoking patients （P〈0.05）, and in NSCLC patients of stage Ⅲ-Ⅳ than NSCLC patients of stage Ⅰ - Ⅱ （P〈0.05）. There was no significant difference in MK levels between adenocarcinoma and squamous carcinoma （P〉0.05）. MK levels of patients who have lymph node metastasis were higher than patients with no lymph node metastasis （P〈0.05）. In the 48 NSCLC patients, Mk levels were significantly decreased after treatment, showing statistically significant difference with those before treatment （P〈0.05）. Conclusion The midkine level of patients with NSCLC has close relationships with pathologi- cal type, clinical stage and smoking, which is a reliable indicator for clinical therapeutic effect.